These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34058788)

  • 21. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
    Miller TW; Amason JD; Garcin ED; Lamy L; Dranchak PK; Macarthur R; Braisted J; Rubin JS; Burgess TL; Farrell CL; Roberts DD; Inglese J
    PLoS One; 2019; 14(7):e0218897. PubMed ID: 31276567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages.
    Sakamoto M; Murata Y; Tanaka D; Kakuchi Y; Okamoto T; Hazama D; Saito Y; Kotani T; Ohnishi H; Miyasaka M; Fujisawa M; Matozaki T
    Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34949714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
    Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms in the human inhibitory signal-regulatory protein α do not affect binding to its ligand CD47.
    Hatherley D; Lea SM; Johnson S; Barclay AN
    J Biol Chem; 2014 Apr; 289(14):10024-8. PubMed ID: 24550402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade.
    Chan C; Stip M; Nederend M; Jansen M; Passchier E; van den Ham F; Wienke J; van Tetering G; Leusen J
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
    Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
    Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
    Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
    Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates.
    Sue M; Tsubaki T; Ishimoto Y; Hayashi S; Ishida S; Otsuka T; Isumi Y; Kawase Y; Yamaguchi J; Nakada T; Ishiguro J; Nakamura K; Kawaida R; Ohtsuka T; Wada T; Agatsuma T; Kawasaki N
    PLoS One; 2024; 19(6):e0304985. PubMed ID: 38843278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
    Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
    Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
    Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
    Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
    Barclay AN; Van den Berg TK
    Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38.
    Li S; Chen D; Yang Y; Guo H; Liu D; Sun N; Bai X; Wang K; Li T; Li G; Yang C; Zhang W; Zhang L; Zhao G; Peng L; Liu S; Tu X; Zhang R; Tian W
    Front Immunol; 2024; 15():1398508. PubMed ID: 38983860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-SIRP
    Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
    JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD47-SIRPα Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation.
    Gondois-Rey F; Miller T; Laletin V; Morelli X; Collette Y; Nunès J; Olive D
    Front Immunol; 2022; 13():899068. PubMed ID: 35795660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
    Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
    Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
    Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
    J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
    Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
    Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
    J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.